| Title： | KSUMC Evidenced-Based Clinical Practice Guideline for Management of Lung Cancer |
| Edition： | Updated |
| Classification： | Standard guideline |
| Field： | Comprehensive guideline |
| Countries and regions： | Saudi Arabia |
| Guidelines users： | Physicians, Nurses and Clinical Pharmacists in the departments of Oncology-Hematology, Internal Medicine (Pulmonology/ Chest), Thoracic Surgery, Pharmacy, Laboratory/ Pathology, Radiology, Nursing and Palliative care teams. |
| Evidence classification method： | The description of the methodology for the production of this adapted CPG can be fulfilled by utilizing the King Saud University (KSU) Modified ADAPTE method. This CPG formal adaptation method included three phases (setup, adaptation, and finalization), nine modules, and 24 steps with modifications in the steps and tools to suit the local general healthcare setting in Saudi Arabia. Overall, the steps of CPG adaptation included the selection of the health topic, formulation of the CPG adaptation working group, identification of health questions using the PIPOH model, searching and selecting Source CPGs with clear inclusion and exclusion criteria, quality assessment of included Source CPGs by using the Appraisal of Guidelines for Research and Evaluation (AGREE) II Instrument, assessment of the currency of the selected Source CPG, drafting of the adapted CPG, external review and consultation process, finalization of the adapted CPG with a set of implementation tools, declaration of conflicts of interests, and finally a plan for review and update. For further details on the specific modifications in steps and tools, refer to the article by Amer et al. 2019 (https://doi.org/10.1111/jep.12927). |
| Development unit： | King Saud University Medical City (KSUMC) |
| Registration time: | 2022-08-22 |
| Registration number： | PREPARE-2022CN541 |
| Purpose of the guideline: | The guideline covers all aspects of the management of patients with small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), and provides information for discussion with patients and carers. The guideline does not address other thoracic malignant disease such as mesothelioma, carcinoma in situ or secondary cancers that have spread to the lungs. Strategies for primary prevention or screening are also out with the remit of the guideline. The guideline does not address the public health issues associated with smoking |
Latest registration
